Alcresta Therapeutics COVID-19 Supply Statement

Most patients treated with RELiZORB fall into the high-risk category of the US population for COVID-19 infection. We are confirming secure access to RELiZORB based on a current assessment of our global supply chain and do not anticipate any potential RELiZORB supply disruption in the mid-term due to the COVID-19 outbreak. We will continue to monitor the situation and take all necessary action in an effort to keep inventories high and ensure supply continuity. Know that we will keep patient advocacy organizations and health care providers informed of any material changes.

For patients with fat malabsorption who require enteral feeding...

Hydrolyze Fats, Normalize Absorption of Fatty Acids

RELiZORB mimics the function of pancreatic lipase and delivers absorbable fats to your patients.

Learn About RELiZORB MOA

In clinical studies, use of RELiZORB was shown to normalize DHA/EPA plasma concentrations to levels consistent with a reference range based on healthy subjects as shown in the literature (please see IFU for full description of the study and references).

This illustration explains how RELiZORB mimics the function of pancreatic lipase and delivers absorbable fats to your patients with fat malabsorption who require enteral feeding.

Starting RELiZORB
Is Simple

See How to Get Patients Started

RELiZORB Achieves
Efficient Fat Hydrolysis

View the Clinical Data

RELiZORB Support
Services

Questions About RELiZORB?

RELiZORB usage backed by recent Consensus Statement in Journal of Cystic Fibrosis

The consensus statement characterizes RELiZORB as a “physiologically superior product,” with “proven success in a real-world setting,” which “can produce measurable, clinically relevant benefits.” The statement further observed that, “despite its effectiveness and intuitive sense, RELiZORB is frequently unavailable to patients due to the vicissitudes of insurance approvals in the US.” This lack of access prompted the authors to develop an independently prepared consensus statement to highlight these patient challenges.

Image of RELiZORB digestive enzyme cartridge used for patients with fat malabsorption who require enteral feeding.

RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing
Medications should not be administered through RELiZORB

For patients with fat malabsorption who require enteral feeding...

Hydrolyze Fats, Normalize Absorption of Fatty Acids

RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

HCP

Final Sequance (vimeo 720p)